Mp40-20 Do Surgeons Wish to Know About Their Long-Term Complications?

Abstract

treatment at 1 and 3 months respectively. Graph I (A,B) showed the discontinuation reasons. 36 out of 92 women were evaluated at 6 months with a high drug adherence (median MMAS-4 score of 0 (range 0-2) ). At 6 months follow-up patient's satisfaction was high, infact median PGI-I and S-VAS were 2 (range 1-4) and 8 (2-10) respectively. At 1,3,6 months OABq-sf score showed a statistically significant improvement with a baseline median score of 36 (range 19-99), of 9 (range 7-24) at 6 months (p¼0.001). Graph 1C showed an improvement of all the OAB symptoms at 1 and 3 months, but they were stable at 6 months. Furthermore a statistically significant decrement of the mean number of pads/die was evident at 6 month (1.45AE1.58 vs 0.57 AE 0.98 p<0.0001).UF results showed no statistical changes at 1 month and at 6 months.The results are not different in women with OAB naïve and women with OAB refractory to antimuscarinic drugs CONCLUSIONS: Mirabegron 50mg showed significant subjective and objective efficacy with a high in women with OAB at 1 and 3 months of treatment. For the low side-effects and its impact on QoL, it can be considered the first line therapy in these patients. Long term results are mandatory for patients perspective and counselling for tailored therapy.